Use of ctDNA in identifying an actionable BRAF mutation in stage 4 metastatic melanoma

被引:0
|
作者
Bennett, Charlotte [1 ]
Morgan, Sian [2 ]
Aboud, Karam [1 ]
Frazer, Ricky Dylan [1 ]
机构
[1] Velindre Univ NHS Trust, Oncol, Cardiff, Wales
[2] All Wales Med Genet Serv, Oncol, Cardiff, Wales
关键词
Skin cancer; Oncology; Malignant disease and immunosuppression; Cancer intervention;
D O I
10.1136/bcr-2022-254268
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The identification of genetic variants in melanoma has enabled the development of targeted therapies. Under the National Institute for Health and Care Excellence (NICE) guidance, patients with BRAF V600E variant are eligible for BRAF and MEK inhibitor therapy. For those with advanced or highly symptomatic disease, a rapid response to treatment is often seen. Current practice relies on tissue biopsy to perform immunohistochemistry (IHC) or next generation sequencing (NGS) to identify these variants; however, this can take up to 2 weeks. In patients with widespread disease, rapid initiation of treatment can be lifesaving.We describe a case in which hotspot circulating tumour DNA (ctDNA) analysis confirmed BRAF variant 6 days prior to biopsy results. This was utilised to expedite treatment initiation and symptomatically, the patient had initial improvement within a few days.This article demonstrates the potential value of ctDNA analysis and the need for further research into this as an alternative to NGS for patients with rapidly progressive disease.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
    Sobczuk, Pawel
    Kozak, Katarzyna
    Kopec, Sylwia
    Rogala, Pawel
    Switaj, Tomasz
    Kosela-Paterczyk, Hanna
    Gos, Aleksandra
    Tysarowski, Andrzej
    Rutkowski, Piotr
    CANCERS, 2022, 14 (03)
  • [2] BRAF-Mutation detection in metastatic Melanoma
    Dietel, M.
    Enk, A.
    Lehmann, A.
    Bauer, J.
    Garbe, C.
    Kellner, U.
    Kirchner, T.
    Jung, A.
    Kreipe, H.
    Merkelbach-Bruse, S.
    Buettner, R.
    Rueschoff, J.
    Schlake, W.
    Schirmacher, P.
    Penzel, R.
    Stadler, R.
    PATHOLOGE, 2012, 33 (04): : 352 - 356
  • [3] Analysis of BRAF mutation in primary and metastatic melanoma
    Libra, M
    Malaponte, G
    Navolanic, PM
    Gangemi, P
    Bevelacqua, V
    Proietti, L
    Bruni, B
    Stivala, F
    Mazzarino, MC
    Travali, S
    McCubrey, JA
    CELL CYCLE, 2005, 4 (10) : 1382 - 1384
  • [4] BRAF Mutation-Positive Folliculotropic Metastatic Melanoma
    Brick, Katherine E.
    Halling, Kevin C.
    Khan, Yulia K.
    Peters, Margot S.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2013, 35 (05) : 609 - 612
  • [5] BRAF mutation as a pejorative marker in metastatic melanoma.
    Brissy, Sophie
    Gaudy-Marqueste, Caroline
    Mallet, Stephanie
    Monestier, Sandrine
    Hesse, Sylvie
    Koeppel, Marie-Christine
    Rojat-Habib, Marie-Christine
    Nanni, Isabelle
    Loundou, Anderson
    Ouafik, L'houcine
    Bonnet, Nathalie
    Richard, Marie-Aleth
    Grob, Jean Jacques
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Patient with stage IV melanoma with BRAF mutation - immunotherapy or BRAF and MEK inhibitors?
    Cybulska-Stopa, Bozena
    Ziobro, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (02): : 100 - 103
  • [7] Recent Comments BRAF Mutation Testing in metastatic malignant Melanoma
    Dietel, Manfred
    Enk, Alexander
    Lehmann, Anita
    Bauer, Juergen N.
    Garbe, Claus
    Kellner, Udo
    Kirchner, Thomas
    Jung, Andreas
    Kreipe, Hans
    Merkelbach-Bruse, Sabine
    Buettner, Reinhard
    Rueschoff, Joseph
    Schlake, Werner
    Schirmacher, Peter
    Stadler, Rudolph
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2012, 10 (06): : 443 - 446
  • [8] Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma
    Ardakani, Nima Mesbah
    Leslie, Connull
    Grieu-Iacopetta, Fabienne
    Lam, Wei-Sen
    Budgeon, Charley
    Millward, Michael
    Amanuel, Benhur
    PIGMENT CELL & MELANOMA RESEARCH, 2017, 30 (02) : 233 - 242
  • [9] Impact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanoma
    Gummadi, Tulasi
    Dronca, Roxana Stefania
    Kim, Chul
    Kottschade, Lisa A.
    Mittapalli, Rajendar K.
    Elmquist, William F.
    Dudek, Arkadiusz
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?
    Gyorki, David E.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (07) : 4014 - 4015